Heretic
Condition

MCAS and histamine

An evidence audit of MCAS and histamine intolerance — what holds up, and what does not.

Updated 16 Oct 202661 sources12 min read

This entry was assembled from its sources; editorial review pending.

This is an evidence audit, not a clinical recommendation. library methodology requires that every strong claim be backed by a primary source we can verify. Where Andra Sitoianu (ND, posting on X as @BioavailableNd and at bioavailablend.substack.com) makes a claim without citing literature, we either locate the supporting peer-reviewed paper or flag the claim as unverified. Where the literature disagrees with her framing, we say so.

01Origin of the audit

@BioavailableNd is a US-licensed naturopathic doctor (ND) whose Substack and X feed reach a large chronic-illness audience. She frames Mast Cell Activation Syndrome (MCAS) as a "total load / bucket" loss of immune tolerance driven by stacked triggers (infections, mold, nickel and metals, hormones, stress), argues mast cells release far more mediators than histamine so antihistamines alone are insufficient, and prescribes a layered protocol of DAO enzyme, beef kidney as a DAO source, low-histamine diet, vitamin C and E, quercetin, nettle, and circadian/sleep work.[1][2] She also links a wide roster of conditions (PCOS, endometriosis, eczema, GERD, ADHD, long COVID) to MCAS, and endorses speculative interventions including organotherapy, cell salts, and nnEMF avoidance.[unverified — paid Substack paywall; only the preview chapter and the open Rosacea/Acne/Nickel posts were retrievable]

This file scores her claims against the primary literature as of 2026-10-15. A companion note MCAS - Diagnostic Criteria and Differential covers the contested consensus-1 vs consensus-2 diagnostic frameworks; DAO and Histamine Degradation covers the enzyme, genetics, and supplement evidence; MCAS - Drivers and Comorbidities rates each specific trigger hypothesis; MCAS - Interventions Evidence Table rates every intervention she promotes.

02Bottom line — claim-by-claim scoring

Ratings use this library's Source Evaluation Framework (5 = RCT/SR; 1 = anecdote). "Translation level" follows the framework's T0–T5 ladder. "Causal confidence" follows the framework's Bradford-Hill add-on.

Andra claim Evidence rating Translation Causal confidence Verdict
MCAS exists as a clinical entity 5 T5 High Supported.
"MCAS as total-load loss of tolerance" framing 3 T3 Low (model, not measured) Plausible model, no direct test.
Mast cells release far more than histamine; H1 antihistamines alone are insufficient 4 T4 High Supported (and the reason cromolyn, leukotriene modifiers, anti-PGD2 drugs exist).[4][30][75]
Consensus-2 vs consensus-1 diagnostic criteria (Molderings/Afrin vs Valent/Akin) 4 T4 — Both exist; the field is split. See MCAS - Diagnostic Criteria and Differential.[3][4][5][9]
DAO enzyme deficiency drives some "histamine intolerance" symptoms 4 T4 Moderate Supported for a subgroup.[12][13][14][15]
DAO enzyme supplementation helps migraine, urticaria, fibromyalgia 3 T3–T4 Moderate Positive small RCTs; not yet a guideline recommendation.[82][83][84]
Beef kidney is a useful DAO source 2 T1 Low Mechanism plausible, no clinical trial. Beef kidney has high B12/selenium but DAO activity in cooked kidney is poorly characterized.[59]
Low-histamine diet relieves HIT symptoms 3 T3 Low–moderate Observational/short RCT support; placebo-controlled DBPC histamine challenges have disproven HIT suspicion in many cases.[12][16][18][131]
Mold/CIRS drives mast cell activation 2 T2 Low Symptom overlap is real, direct MCAS-from-mold evidence is weak.[27][28][111][112]
Nickel acts like an estrogen and activates mast cells 3 T2–T3 Moderate (estrogen-like); low (mast cell) Nickel as metalloestrogen is established in vitro.[47] Nickel as mast cell activator is plausible in sensitized hosts (SNAS) but not robust.
Nickel allergy → endometriosis risk 3 T3 Moderate (association) Population-based cohort studies confirm association, but causality and mechanism unclear.[49][50]
MCAS after COVID 3 T3 Moderate Mast-cell-related symptoms are prevalent in long COVID, but consensus-1 MCAS criteria may not be met.[21][22][38]
DAO capacity falls with age 3 T3 Moderate Plasma DAO is reduced in aging and in some chronic disease states, but the clinical implication is debated.[12][15]
Vitamin C lowers blood histamine 3 T3 Moderate (in depleted subjects) Real in vivo effect under specific conditions; not a universal mast-cell stabilizer.[132][133][134][135][44][45]
Quercetin stabilizes mast cells 3 T2–T3 Moderate In vitro/in vivo mechanistic evidence; clinical outcomes modest and indirect (niacin flush).[86][89]
Nettle (Urtica dioica) inhibits H1 and mast-cell tryptase 2 T1–T2 Low In vitro only; no clinical trial in MCAS.[31]
Sleep / circadian disruption worsens mast cell activity 2 T2 Low Mechanistic and animal evidence; very limited human MCAS sleep studies.[116][117]
ADHD is a histamine problem 1 T1 Very low Animal mechanism (H2 receptors in dopaminergic circuits) exists; no human trial of antihistamines in ADHD.[55][56][57]
nnEMF drives mast cell degranulation 1 T1 Very low Animal histology only; no human MCAS trial.[52][53]
Organotherapy treats MCAS 1 T0 None No primary literature; historical use only.[104]
Cell salts (biochemic tissue salts) treat MCAS 1 T0 None No primary literature; not in any modern evidence base.[105]

Swipe table →

One-sentence read: The mast cell biology is real, the DAO/migraine evidence is the strongest part of her protocol, and the low-histamine diet helps some and is unproven for many; everything beyond that — the broad condition list, the "histamine = ADHD" framing, nnEMF, organotherapy, cell salts — is either mechanistic speculation or unsupported clinical claim. Treat her work as a clinical map of what might work in a layered, total-load approach, not as a validated treatment protocol.

03What MCAS actually is

Mast cells are tissue-resident immune sentinels concentrated at environmental interfaces (skin, gut, respiratory tract) and in nerve-rich connective tissue.[4][30] On activation they release preformed mediators (histamine, tryptase, heparin, chymase) and newly synthesized mediators (prostaglandin D2, leukotrienes C4/D4/E4, cytokines TNF-α and IL-6, and others).[4][30][75] Because they sit next to nerve endings and vessels, their mediators explain the characteristic multi-system pattern (flushing, urticaria, angioedema, abdominal pain, diarrhea, palpitations, brain fog, dyspnea).

The 2024 JACI characterization of 413 patients (Weiler) and the 2021 Valent update of WHO classification are the canonical sources for what MCAS is not confused with (systemic mastocytosis, IgE allergy, carcinoid, pheochromocytoma) and how to test for it.[1][75][34] See MCAS - Diagnostic Criteria and Differential for the consensus-1 vs consensus-2 split — this is the single biggest source of disagreement in the field, and it's also why Andra's "broad" claim that MCAS underlies PCOS, endometriosis, ADHD, and GERD is contested.[4][9][5][3]

04What Andra gets right

  1. Mast cells release far more than histamine; antihistamines alone are not enough. Strong support from primary literature.[4][30][75] That is why cromolyn (mast-cell stabilizer), leukotriene receptor antagonists (montelukast), and prostaglandin antagonists are part of mainstream MCAS treatment.[30][63] Weiler reported that H1 antihistamines help ~70% of MCAS patients but rarely resolve all symptoms.[75]

  2. DAO enzyme deficiency is real for some patients. Plasma DAO can be low in HIT; oral DAO reduces symptoms in small positive RCTs in migraine (n=39, double-blind, p<0.05 for attack reduction), chronic spontaneous urticaria (n=56, double-blind), and fibromyalgia (n=39, double-blind).[82][83][84]

  3. Vitamin C reduces blood histamine, but only in depleted populations and at high doses. The 1980 Hagström depletion-repletion study and the 1992 Johnston trial showed ascorbate at 1–3 g/day drops whole-blood histamine in scorbutic or low-baseline subjects.[134][135][44][132][133]

  4. Quercetin has mast-cell-stabilizing activity. In vitro, in animal models, and in a small niacin-flush human study.[86][89]

  5. Nettle extract inhibits H1 receptor and mast cell tryptase in vitro. No clinical trial in MCAS, but the mechanism is real.[31]

  6. Sleep and circadian effects on mast cells exist. Tryptase shows modest circadian variation in venom-allergic subjects; animal and in vitro work links BMAL/clock genes to mast cell reactivity.[116][117]

  7. Nickel allergy is associated with endometriosis in epidemiological cohorts. Two population-based studies (3-year and 11-year) found significantly higher nickel allergy prevalence in endometriosis patients.[49][50]

  8. Mast-cell-related symptoms are highly prevalent in long COVID. A 2022 long-COVID survey (Afrin et al.) found that mast-cell activation symptom inventories substantially overlap with long-COVID symptom inventories.[38]

  9. Hyperadrenergic POTS, hypermobile EDS, and MCAS cluster together. The association is "firmly established" by 2024 multidisciplinary consensus; a clinical practice update from the AGA covers the GI manifestations.[147][71]

05What Andra gets partially right (mechanism is real, evidence is thin or contested)

  1. MCAS as a "total-load" loss of tolerance. The framing is reasonable: triggers stack, mast cells respond to many signals (IgE, complement, neuropeptides, CRH, estrogen, TLR ligands, cytokines, hormones), and stress/CRH increase intestinal permeability via mast cells.[110] But "total load" is a clinical heuristic, not a measured variable, and the model has not been tested against an alternative (e.g., does triaging mold exposure vs. nickel avoidance vs. estrogen modulation each independently reduce tryptase flares?). It is a useful organizing framework, not a diagnostic or therapeutic standard.

  2. Mold / CIRS drives MCAS. CIRS (Shoemaker protocol) and MCAS share symptom patterns and inflammatory markers (TGF-β1, MMP9, C4a, VEGF), and clinical reviews note the overlap.[28][111][112] But (a) the CIRS literature is dominated by a single research group (Shoemaker et al.), (b) independent replication is thin, (c) at least one in vitro study shows the common Aspergillus metabolite gliotoxin suppresses mast cell activation (opposite of "mold drives mast cells").[27] Treat the overlap as plausible but unproven.

  3. Nickel activates mast cells. In the SNAS population this is documented: oral hyposensitization to nickel reduces symptoms, low-nickel diets resolve extra-cutaneous symptoms, and SNAS patients show mast-cell-like GI and skin flares after nickel challenge.[10][11][81][80] In non-sensitized populations, nickel is more often described as an allergen (Type IV) than as a mast cell trigger.

  4. Estrogen drives mast cell degranulation in reproductive tissue. A 2017 study showed E2 directly triggers mast-cell mediator release (hexosaminidase, NGF) in RBL2H3 cells and increases MC recruitment via stem cell factor/TGF-β/MCP-1 from endometriotic cells.[20] This is real but is a reproductive-tissue story, not a general "E2 → MCAS" story.

  5. DAO capacity falls with age. Plasma DAO activity is reported to decline with age and in some GI diseases (IBD, celiac, chronic gastritis).[15][12] The clinical implication ("older people should supplement DAO") is not tested.

  6. Low-histamine diet relieves HIT in some patients. Observational data and small open-label trials are positive, but the only DBPC oral histamine challenge in suspected HIT subjects failed to provoke symptoms in most of them, casting doubt on the population.[18][131]

06What Andra gets wrong or unsupported

  1. ADHD as a "histamine problem." Animal data (H2 receptors on parvalbumin-positive neurons in substantia nigra pars reticulata; H2 modulation of striatal dopamine) shows a real histamine–dopamine circuit.[55][56][57] There is no human RCT of antihistamines in ADHD that I located. This is a mechanistic hypothesis, not a clinical recommendation.

  2. nnEMF as a mast cell driver. The published animal evidence is histology-level: combined atrazine + 50 Hz EMF exposure increased cutaneous mast cell degranulation in juvenile rats; ELF-EMF increased thyroid mast cell density.[52][53] No human MCAS trial. The "nnEMF → dysbiosis → MCAS → depression" framework is a hypothesis chain built on inference, not a measured cascade.

  3. Organotherapy and cell salts for MCAS. Organotherapy (injecting or ingesting animal glandular extracts to treat the corresponding human organ) is a 19th-century practice with no modern evidence base for MCAS or any related condition.[104] Cell salts (biochemic tissue salts, Schuessler) similarly have no peer-reviewed primary literature supporting their use in MCAS.[105] Both appear in complementary-medicine surveys but not in any allergy, immunology, or mast-cell literature.

  4. Her long condition list linked to MCAS (PCOS, eczema, GERD, ADHD, etc.). Each of these has at most fragmentary or hypothesis-level evidence linking it to MCAS. See MCAS - Drivers and Comorbidities for the per-condition audit.

  5. "Beef kidney as a DAO source." There is no clinical trial of beef-kidney consumption in HIT. Beef kidney is exceptionally nutrient-dense for selenium, B12, B2, folate, and copper (per Organ Meats and Nose-to-Tail), and is sometimes claimed to be high in DAO. A 2023 in vitro enzymatic assay (PMID 31655856) measured DAO activity in food matrices, but I did not find a quantification of residual DAO activity in cooked beef kidney — cooking likely denatures the enzyme.

07Practical Notes (intervention rating table — see companion file for detail)

Intervention Andra's role Evidence rating Translation Practical note
H1/H2 antihistamines Foundation (but "not enough") 4 T4 First-line in mainstream MCAS care.[63][75]
Cromolyn sodium Mast cell stabilizer 3 T3 Effective in MCAS, ME/CFS, and pediatric MCAS case series.[26][65]
Oral DAO enzyme (porcine kidney extract) Pre-meal 3 T3–T4 Positive RCTs in migraine, urticaria, fibromyalgia.[82][83][84]
Low-histamine diet Foundation 3 T3 Helps some, fails DBPC challenge in many suspected HIT.[12][18]
Vitamin C (1–3 g) Antihistamine 3 T3 Drops whole-blood histamine in depleted subjects.[132][135]
Quercetin (often 500–1000 mg) Mast cell stabilizer 3 T2 Modest clinical effect; most evidence is mechanistic.[89]
Luteolin Mast cell stabilizer 2 T1 Open-label pediatric autism pilot only.[88]
Nettle (Urtica dioica) Antihistamine / mast cell 2 T1 In vitro only.[31]
Sleep / circadian work Foundation 3 T3 Tryptase varies modestly across the day; sleep fragmentation worsens inflammation.[116][117]
Stress / limbic retraining (DNRS) Foundation 1 T1 No primary MCAS trial.[unverified]

Swipe table →

08Method note

Sources are PubMed-indexed primary literature fetched 2026-10-15 via NCBI E-utilities. Andra's paywalled MCAS protocol post was not directly accessible; her open Substack posts (Rosacea, Acne, Nickel-IBS/IBD) and her public X timeline were used to characterize her claims. this library convention (Research Methodology) requires primary-source citations for any claim rated ≥3; this file uses only PubMed/PMC-anchored citations for mechanistic and clinical claims, and labels higher-tier speculation [unverified].

09Notes

  • Andra's protocol post is paywalled. Public preview mentions "dozens of chemical messengers" beyond histamine, which matches the primary literature.[4][75] Full assessment of her specific protocol details (dosage, sequencing, brand recommendations) requires subscription.
  • The single biggest issue with her framing is not whether MCAS exists — it does — but what counts as MCAS. Consensus-1 (Valent/Akin, 2019/2024) is more restrictive; consensus-2 (Afrin/Molderings) is broader and includes more patients.[4][5][9] See MCAS - Diagnostic Criteria and Differential.
  • A 2024 study of 703 suspected MCAS patients at a tertiary referral center found that only a small minority met consensus-1 criteria for idiopathic MCAS — most had alternative or comorbid explanations.[128] This is a real-world reality check on the explosion of self-diagnosed MCAS.

10Connections

Neighborhood · 8 linked entriesOpen full map →
SleepGuide · 18 links→ Mold illness and CIRSCondition · 10 links→ Organ meatsDiet · 7 links→ DAO and histamine degradationMechanism · 6 links→ MCAS diagnostic criteriaGuide · 6 links→ MCAS drivers and comorbiditiesGuide · 6 links→ MCAS interventions evidenceGuide · 6 links→ MCAS claims audit (Andra Sitoianu)Guide · 5 links→

11Sources

  1. PubMed 31655856PubMed 31655856
  2. PubMed 34901755PubMed 34901755
  3. PubMed 42240520PubMed 42240520
  4. PubMed 38243020PubMed 38243020
  5. PubMed 32324159PubMed 32324159
  6. PubMed 31470118PubMed 31470118
  7. PubMed 35605594PubMed 35605594
  8. PubMed 41994619PubMed 41994619
  9. PubMed 21409856PubMed 21409856
  10. PubMed 38674909PubMed 38674909
  11. PubMed 40865824PubMed 40865824
  12. PubMed 34209583PubMed 34209583
  13. PubMed 17490952PubMed 17490952
  14. PubMed 39796463PubMed 39796463
  15. PubMed 37648152PubMed 37648152
  16. PubMed 29074615PubMed 29074615
  17. PubMed 35785029PubMed 35785029
  18. PubMed 35938771PubMed 35938771
  19. PubMed 30964355PubMed 30964355
  20. PubMed 16213796PubMed 16213796
  21. PubMed 36069791PubMed 36069791
  22. PubMed 30961835PubMed 30961835
  23. PubMed 19140159PubMed 19140159
  24. PubMed 41285202PubMed 41285202
  25. PubMed 34563706PubMed 34563706
  26. PubMed 25664905PubMed 25664905
  27. PubMed 25095772PubMed 25095772
  28. PubMed 16489580PubMed 16489580
  29. PubMed 26439741PubMed 26439741
  30. PubMed 25976177PubMed 25976177
  31. PubMed 20148244PubMed 20148244
  32. PubMed 15813213PubMed 15813213
  33. PubMed 42763339PubMed 42763339
  34. PubMed 40355265PubMed 40355265
  35. PubMed 39788124PubMed 39788124
  36. PubMed 26095756PubMed 26095756
  37. PubMed 41728426PubMed 41728426
  38. PubMed 40387691PubMed 40387691
  39. PubMed 28262205PubMed 28262205
  40. PubMed 25363062PubMed 25363062
  41. PubMed 20378005PubMed 20378005
  42. PubMed 37892588PubMed 37892588
  43. PubMed 29698966PubMed 29698966
  44. PubMed 29475774PubMed 29475774
  45. PubMed 40362785PubMed 40362785
  46. PubMed 23688534PubMed 23688534
  47. PubMed 18831918PubMed 18831918
  48. PubMed 40396860PubMed 40396860
  49. PubMed 10859600PubMed 10859600
  50. PubMed 24153250PubMed 24153250
  51. PubMed 29752039PubMed 29752039
  52. PubMed 29880330PubMed 29880330
  53. PubMed 41915304PubMed 41915304
  54. PubMed 15813817PubMed 15813817
  55. PubMed 38056692PubMed 38056692
  56. PubMed 15603203PubMed 15603203
  57. PubMed 15050101PubMed 15050101
  58. PubMed 12611642PubMed 12611642
  59. PubMed 8951736PubMed 8951736
  60. PubMed 1578094PubMed 1578094
  61. PubMed 40352770PubMed 40352770

12Entry history

Latest content update.

Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.